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abine. All patients received ATG to prevent graft rejection.
Donors were matched related (8) andmatched unrelated (4).
BM grafts were depleted of T-cells using the soybean
agglutinin method followed by sheep RBC rosetting, and PB
grafts by immunomagnetic CD34+ selection (Isolex initially
and CliniMACS after 09/2011).
Results: Three pts died early and were not evaluable for
engraftment, the remaining 9 pts engrafted. None of these pts
developed acute or chronic GvHD after the primary graft. Of
the 9 pts evaluable for long term follow up, 8 are alive with a
median follow up time of 12.1 months (3.3-196months). One
pt relapsed 15 months post initial transplant and achieved
remission after DLI. This patient developed acute gut GVHD
that responded to steroids. Two additional pts received low
dose DLI (0.5x106CD3 cells/kg), one for recurrent viral in-
fections and the other as prophylaxis for relapse. These 2 pts
had no GvHD post-DLI. Out of the 4 pts who did not undergo
pre-transplant splenectomy, one required post transplant
splenectomy for severe persistent thrombocytopenia which
resolved post splenectomy. JAK2 mutation was not detected
post transplant in any of the 3 pts.
In this small series of pts, eight out of twelve, 66%, are
alive; two of the ﬁve pts in the subgroup cyto-reduced with
TBI based regimen and six of the seven patients in the sub-
group cyto-reduced with chemotherapy only regimen. The
causes of death were: toxicity of the preparative regimen
(TBI) in 2, intra-cranial hemorrhage in 1 and unknown in the
4 thpatient who died more than 2 years post transplant with
no evidence of disease.
Conclusions: TCD transplantation can offer long term cure
for patients with advanced chronic MF and with no evidence
of GvHD in this small cohort of patients. The early experience
at MSKCCwith TCD transplant was associatedwith high rates
of early mortality likely related to the high intensity condi-
tioning regimen containing TBI. The current regimen of
busulphan, melphalan, ﬂudarabine and ATG has been well
tolerated and the majority of pts are alive and disease free.393
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Aim: Multicenter phase II study has been conducted to
investigate whether myeloablative dose of intravenous
busulfan (ivBu) can be used for elderly recipients.
Method: This study started in September 2009, and 32
centers participated (Trial identiﬁer: UMIN000002426). Pa-
tients aged from 55 to 70with acutemyeloid leukemia (AML)
or myelodysplastic syndrome (MDS) who were planned for
allo-SCT (bone marrow (BM), peripheral blood (PB), and cord
blood (CB)) were enrolled. Pretransplant conditioining con-
sisted of 30 mg/m2 of ﬂudarabine (Flu) for 6 days (total 180
mg/m2) and 3.2 mg/kg of ivBu for 4 days (divided by 4 daily,
total 12.8 mg/kg) with or without total body irradiation
depending on type of donor cells. Calcineurine inhibitors +
methotrexate for BM or PB recipients, and tacrolimus +
mycophenolate mofetil were used for CB recipients.
Result: Thirty-eight patients were enrolled. Median age was
60 (55-68), 22 male and 16 female, 31 AML and 7 MDS were
included. Donors were 8 matched and 2 1-Ag/allele-mis-
matched related BM/PB, 8 matched and 4 1-Ag/allele-mis-
matched unrelated BM, and 16 CB (2-Ag-mismatched).
There was 1 whose total dose of ivBu was reduced (11.2 mg/
kg) due to neurotoxicity (grade III). Thirty-ﬁve achieved
neutrophil recovery (median day 17 (range, 11-45)). There
was 1 who died from NRM early before engraftment (CB
recipient, day 27) due to cerebral hemorrhage, and were 2
who failed to engraft (both CB recipients, one due to early
relapse, and the other due to rejection). There were 2 VOD/
SOS observed. Cumulative incidences of grade II-IV and III-IV
acute GVHD were 37% and 16%, respectively. With respect to
donor type, no grade III-IV acute GVHD was observed in
transplants from matched related donors. Cumulative
incidence of total chronic GVHD was 38%. Up to 24 months
post-transplant, there were 11 relapse, and 7 non-relapse
mortality. Cumulative incidences of non-relapse mortality
and relapse at 2-year post-transplant were 21% and 31%,
respectively. Overall and event-free survivals were estimated
to be 58 % and 53 % at 2 year post-transplant.
Conclusions: Myeloablative conditioning using Flu/ivBu12.8
mg/kg +/- TBI was well tolerated with acceptable low toxic-
ities and was sufﬁcient to allow donor cell-engraftment post
allo-SCT for elderly patients with AML or MDS. Given the
promising results of OS and PFS, phase II studies in much
larger scale are now under investigation.394
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Background: Inﬂuenza is one of the most common virus
causing respiratory tract infection in HM patients and HSCT
recipients. Severely immunocompromised pts suffer more
severe disease, prolonged viral shedding, emergence of
resistance as well as highermortality rate. Studies comparing
characteristics and outcomes of pandemic H1N1 and
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cipients are lacking.
Methods: We evaluated characteristics, diagnostic results,
management and outcomes of all inﬂuenza A infections
(pandemic H1N1 versus SFlu) and determined the risk fac-
tors associated with pneumonia and all-cause mortality in
HM patient and HSCT recipients at MD Anderson Cancer
Center (MDACC) from April 2009 to July 2013.
Results: A total of 259 patients were identiﬁed, including 134
(52%) HMpatients and 125 (48%) HSCT recipients. Majority of
patients (242, 93%) were adults, males (147, 57%) with un-
derlying diseases in remission (160, 64%). About half of pa-
tients required hospitalization for outcomes including
pneumonia 28% (72 pts) and death 6% (16 pts). Majority of
patients (214, 83%) received antiviral therapy within a me-
dian of 3 days (range, 0d e 28d) after onset of ﬁrst symptom.
Compared to HCT recipients, a signiﬁcantly higher percent-
age of HM pts were in active stages of cancer with severe
neutropenia (26, 20%) and severe lymphopenia (25, 19%) and
required hospitalization (76, 57%). Multivariable logistic
regression analysis identiﬁed hematologic malignancy (AOR:
2.5 (95% CI: 1.2, 5.28), decreased albumin (AOR: 2.2 (95% CI:
1.0, 4.64), and delay in initiation of antiviral therapy (AOR:
1.3 (95% CI: 1.12, 1.47) as signiﬁcant risk factors for devel-
opment of pneumonia (P¼ 0.05), after adjusting for the virus
strain. Interestingly, H1N1 infections were more prevalent in
Hispanic population (26, 31%) and requiredmore mechanical
ventilation (9, 11%) compared to SFlu, but no signiﬁcant dif-
ferences were observed with respect to pneumonia or mor-
tality between these two viruses.
Conclusions: Inﬂuenza remains a signiﬁcant cause of
morbidity and mortality in HM patients and HSCT recipients.
Compared to HCT recipients, HM patients weremore likely to
progress to pneumonia, probably owing to active cancer
stage and pancytopenia. H1N1 patients did not have higher
mortality rate compared to SFlu in either of the groups. Early
antiviral therapy remains crucial in preventing morbidity in
this population.395
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Background: Thalassemia syndromes are very prevalent in
many parts of the world including Asia. Allogeneic hemato-
poietic cell transplantation (HCT) is the only curative therapy
accepted worldwide.
Objectives: To assess outcomes of HCT for thalassemias and
hemoglobinopathies in single medical center in Thailand.
Methods: Case series study for thalassemia and hemoglo-
binopathy patients undergoing HCT at Bangkok Hospital
Medical Center from February 2009 thru October 2013.
Results: Therewere totally 14 patients. 10 cases were Thais, 1
was French-Thai, 1 was Bangladeshi, 1 was Lao, and 1 was
Omani who had sickle cell disease (SCD). 12 cases were
diagnosed as beta-thalassemia/hemoglobin E diseases, 1 as
transfusion-dependent alpha-thalassemia, and 1 as SCD.
Among 14 HCTs, 9 patients underwent bone marrow trans-
plant (BMT), 4 patients underwent umbilical cord blood
transplant (CBT), and 1 patient underwent combined cordblood and marrow transplantation. All 14 related donors
were fully-HLA-matched, 4 had normal typing, 9 had thal-
assemia trait, and 1 had sickle cell trait. Male to female pa-
tients ratiowere 11:3. Patients’ ages at transplant varied from
2 years to 15 years 11 months with median of 4 years 10
months. Patient’s body weight varied from 11.1 to 50 kilo-
gram (median 17.2 kilogram). According to Pesaro classiﬁ-
cation, among 13 thalassemia patients there were 8 class I,
and 5 class II patients. Busulfan, ﬂudarabine, and rabbit ATG
were mainly used as myeloablative conditioning regimen.
Cyclosporine and short-course methotrexate were mainly
used as graft-versus-host disease (GvHD) prophylaxis in BMT
group, while cyclosporine alone was used in CBT group.
CD34+ cell doses per kilogram body weight recipients were
ranged from 5.6 to 34.7x106 (median 11.3x106) in BMT group
(n¼9), and from 1.6 to 3x105 (median 2.3x105) in CBT group
(n¼4). Complete donor engraftments were achieved in 11
patients. Mixed-chimerism states with donor predominance
were present in 2 patients from BMT and 1 patient from CBT
group. No patients experienced graft failure. Neutrophil re-
coveries were evident on days +10 to +23 (median day +14),
and platelet recoveries were observed on days +19 to +64
(median day +40). 2 patients had mild veno-occlusive dis-
eases and were later completely reversible. No patients
developed acute or chronic GvHD. Therewere no mortalities.
1 patient had treatable pneumocystis pneumonia at 4
months post CBT. Median follow-up time for all patients was
2 years (1 month to 4 years 8 months). Overall (OS) and
disease-free survival (DFS) were 100% and 100% for all pa-
tients (n¼14). Based on risk class, the OS and DFS for class I
thalassemia patients (n¼9) were 100% and 100%, and class II
patients (n¼4) were 100% and 100%, respectively.
Conclusions: Our experiences in HCT for thalassemias and
hemoglobinopathies were very favorable. Regular follow-up
visits are encouraged to determine long term outcomes.396
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We developed a 2 step haploidentical HSCT where 76 pa-
tients received myeloablative or reduced intensity regimens
followed by a DLI containing a ﬁxed dose of 2.0 x 108/kg T
cells (HSCT step 1). After 2 days, 60mg/kg/d x 2 of CY was
infused, followed a day later by a CD34 selected PBSC product
[HSCT step 2 median dose 5 x 106/kg (range 1.64-10)]. We
concurrently used a 1 step HSCT approach in a group of 16
patients, 8 with unrelated donors (URD) and 8 patients (6
with haploidentical, 2 with matched related donors) with
comorbidities precluding eligibility for the 2 step protocol.
The 1 step patients were given the same conditioning, but
afterwards received unmanipulated PBSC’s [median CD 34
dose 7.18x106/kg, (range 4.41-10); median T cell dose 2.9 x
108/kg, (range 1.4-3.90)]. CY 60mg/kg/d x 2 was infused 48
